Search

Your search keyword '"Naaktgeboren, C A"' showing total 158 results
Start Over Author "Naaktgeboren, C A"
158 results on '"Naaktgeboren, C A"'

3. Evaluation of low-dose aspirin in the prevention of recurrent spontaneous preterm labour (the APRIL study): A multicentre, randomised, double-blinded, placebo-controlled trial

Author

Landman, Anadeijda J.E.M.C., Boer, M.A. de, Visser, Laura, Nijman, T.A., Hemels, M.A.C., Naaktgeboren, C., Drongelen, J. van, Groot, C.J. de, Oudijk, M.A., Landman, Anadeijda J.E.M.C., Boer, M.A. de, Visser, Laura, Nijman, T.A., Hemels, M.A.C., Naaktgeboren, C., Drongelen, J. van, Groot, C.J. de, and Oudijk, M.A.

Abstract

Contains fulltext : 249784.pdf (Publisher’s version ) (Open Access)

Published
2022

5. Aspirin versus placebo for the prevention of recurrent preterm labor: APRIL trial

Author

Landman, A., de Boer, M., Visser, L., Nijman, T., Hemels, M., Naaktgeboren, C., Jansen-van der Weide, M., Mol, B., van Laar, J., Papatsonis, D., Bekker, M., van Drongelen, J., van Pampus, M., Sueters, M., van der Ham, D., Sikkema, M., Zwart, J., Huisjes, A., van Huizen, M., Kleiverda, G., Boon, J., Franssen, M., Hermes, W., Visser, H., de Groot, C., Oudijk, M., Obstetrics and gynaecology, Pathology, Gastroenterology and hepatology, Urology, Internal medicine, and Amsterdam Reproduction & Development

Published
2021

6. Lattice Nomenclature Survey from LGA to Modern LBM

Author

de Andrade, Felipe and Naaktgeboren, C

Subjects
bepress|Engineering|Mechanical Engineering|Heat Transfer, Combustion, bepress|Physical Sciences and Mathematics|Physics|Engineering Physics, engrXiv|Engineering|Engineering Physics, engrXiv|Engineering, bepress|Engineering, High Energy Physics::Lattice, engrXiv|Engineering|Mechanical Engineering|Fluid Mechanics, bepress|Engineering|Aerospace Engineering|Aerodynamics and Fluid Mechanics, bepress|Engineering|Mechanical Engineering, engrXiv|Engineering|Mechanical Engineering, engrXiv|Engineering|Mechanical Engineering|Heat Transfer
Abstract

Lattice configuration is a core parameter in Lattice-Boltzmann (LB) methods, both from theoretical and implementation standpoints. As LB methods have progressed over the past decades, a variety of lattice configurations have been proposed and referred to according to a plurality of lattice nomenclature systems that usually include the Euclidean space dimensionality, the lattice velocity count and, in fewer instances, the discretization order in their format. This work surveys lattice nomenclature systems, or lattice naming schemes, along the history of LB methods, starting from their Lattice Gas Automata (LGA) predecessor method, up to the present time. Findings include multiple lattice categories, competing naming standards, ambiguous names particularly in higher-order models, naming systems of varying model parameter scopes, and lack of unambiguous naming schemes even for space-filling, Bravais lattice types.

Published
2020

7. On Illustrating Carnot’s General Proposition by Means of Reversible Stirling Engines

Author

Beck, Klunger, Lafay, Jean-Marc, and Naaktgeboren, C

Subjects
engrXiv|Engineering, bepress|Engineering, bepress|Engineering|Mechanical Engineering, engrXiv|Engineering|Mechanical Engineering, engrXiv|Engineering|Mechanical Engineering|Energy Systems, bepress|Engineering|Mechanical Engineering|Energy Systems
Abstract

Carnot’s general proposition, also referred to as one of Carnot’s principles, states that the work producing potential of heat—harvested by reversible heat engines—is independent on the working fluid and on engine internal details, being only a function of the temperatures of the reservoirs with which the engine exchanges heat. This concept, usually presented to ME students in the context of the second law of thermodynamics, is usually proven by contradiction, using second law concepts and abstractions, without concrete examples, even though Carnot’s proposition mentions concrete things such as working fluids and engine internal details. This work proposes to document the usage of reversible Stirling engine models that take the engine arrangement and fluid properties into account towards illustrating the validity of Carnot’s general proposition.

Published
2020
Full Text
View/download PDF

8. On Exact and Local Polytropic Processes: Etymology, Modeling, and Requisites

Author

Naaktgeboren, C

Subjects
engrXiv|Engineering, bepress|Engineering, bepress|Engineering|Mechanical Engineering, engrXiv|Engineering|Mechanical Engineering, engrXiv|Engineering|Mechanical Engineering|Energy Systems, bepress|Engineering|Mechanical Engineering|Energy Systems
Abstract

This preprint concerns polytropic processes, a fundamental process type in engineering thermodynamics. An etymology is presented for the term, and the ties to its usefulness are identified. The seemingly new support concept of ‘logical’ thermodynamic process, as well as the seemingly new working concept of ‘exact’ polytropic process, and a statement for ‘local’ polytropic process, are herein provided. The proposition of employing local polytropic processes as computational discrete elements for generic engineering thermodynamics process modeling is made. Finally, theoretical requisites for a process to be an exact polytropic one, including the deduction of the most general equation of state of the underlying substance, are discussed beyond a reference.

Published
2020
Full Text
View/download PDF

9. Thyroid-stimulating hormone and free thyroxine fail to predict the severity and clinical course of hyperemesis gravidarum: A prospective cohort study

Author

Nijsten, K., Koot, M.H., Post, J.A.M. van der, Bais, J.M., Ris-Stalpers, C., Naaktgeboren, C., Bremer, H.A., Ham, D.P. van der, Heidema, W.M., Huisjes, A., Kleiverda, G., Kuppens, S.M., Laar, J. van, Langenveld, J., Made, F. van der, Papatsonis, D., Pelinck, M.J., Pernet, P.J., Rheenen-Flach, L. van, Rijnders, R.J., Scheepers, H.C., Siegelaar, S.E., Vogelvang, T., Mol, B.W.J., Roseboom, T.J., Grooten, I.J., Painter, R.C., Nijsten, K., Koot, M.H., Post, J.A.M. van der, Bais, J.M., Ris-Stalpers, C., Naaktgeboren, C., Bremer, H.A., Ham, D.P. van der, Heidema, W.M., Huisjes, A., Kleiverda, G., Kuppens, S.M., Laar, J. van, Langenveld, J., Made, F. van der, Papatsonis, D., Pelinck, M.J., Pernet, P.J., Rheenen-Flach, L. van, Rijnders, R.J., Scheepers, H.C., Siegelaar, S.E., Vogelvang, T., Mol, B.W.J., Roseboom, T.J., Grooten, I.J., and Painter, R.C.

Abstract

Item does not contain fulltext, INTRODUCTION: Little is known about the pathophysiology of hyperemesis gravidarum (HG). Proposed underlying causes are multifactorial and thyroid function is hypothesized to be causally involved. In this study, we aimed to assess the utility of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) as a marker and predictor for the severity and clinical course of HG. MATERIAL AND METHODS: We conducted a prospective cohort study including women admitted for HG between 5 and 20 weeks of gestation in 19 hospitals in the Netherlands. Women with a medical history of thyroid disease were excluded. TSH and FT4 were measured at study entry. To adjust for gestational age, we calculated TSH multiples of the median (MoM). We assessed HG severity at study entry as severity of nausea and vomiting (by the Pregnancy Unique Quantification of Emesis and nausea score), weight change compared with prepregnancy weight, and quality of life. We assessed the clinical course of HG as severity of nausea and vomiting and quality of life 1 week after inclusion, duration of hospital admissions, and readmissions. We performed multivariable regression analysis with absolute TSH, TSH MoMs, and FT4. RESULTS: Between 2013 and 2016, 215 women participated in the cohort. TSH, TSH MoM, and FT4 were available for, respectively, 150, 126, and 106 of these women. Multivariable linear regression analysis showed that lower TSH MoM was significantly associated with increased weight loss or lower weight gain at study entry (ΔKg; β = 2.00, 95% CI 0.47-3.53), whereas absolute TSH and FT4 were not. Lower TSH, not lower TSH MoM or FT4, was significantly associated with lower nausea and vomiting scores 1 week after inclusion (β = 1.74, 95% CI 0.36-3.11). TSH and FT4 showed no association with any of the other markers of the severity or clinical course of HG. Twenty-one out of 215 (9.8%) women had gestational transient thyrotoxicosis. Women with gestational transient thyrotoxicosis had a lower quality of life

Published
2021

10. The Impact of a Standardized Pre-visit Laboratory Testing Panel in the Internal Medicine Outpatient Clinic:a Controlled “On-Off” Trial

Author

Vrijsen, B. E.L., ten Berg, M. J., Naaktgeboren, C. A., Vis, J. Y., Dijstelbloem, H. M., Westerink, J., Dekker, D., Hoefer, I. E., Haitjema, S., Hulsbergen-Veelken, C. A.R., van Solinge, W. W., Kaasjager, H. A.H., Vrijsen, B. E.L., ten Berg, M. J., Naaktgeboren, C. A., Vis, J. Y., Dijstelbloem, H. M., Westerink, J., Dekker, D., Hoefer, I. E., Haitjema, S., Hulsbergen-Veelken, C. A.R., van Solinge, W. W., and Kaasjager, H. A.H.

Abstract

Background: In several settings, a shorter time to diagnosis has been shown to lead to improved clinical outcomes. The implementation of a rapid laboratory testing allows for a pre-visit testing in the outpatient clinic, meaning that test results are available during the first outpatient visit. Objective: To determine whether the pre-visit laboratory testing leads to a shorter time to diagnosis in the general internal medicine outpatient clinic. Design: An “on-off” trial, allocating subjects to one of two treatment arms in consecutive alternating blocks. Participants: All new referrals to the internal medicine outpatient clinic of a university hospital were included, excluding second opinions. A total of 595 patients were eligible; one person declined to participate, leaving data from 594 patients for analysis. Intervention: In the intervention group, patients had a standardized pre-visit laboratory testing before the first visit. Main Measures: The primary outcome was the time to diagnosis. Secondary outcomes were the correctness of the preliminary diagnosis on the first day, health care utilization, and patient and physician satisfaction. Key Results: There was no difference in time to diagnosis between the two groups (median 35 days vs 35 days; hazard ratio 1.03 [0.87–1.22]; p =.71). The pre-visit testing group had higher proportions of both correct preliminary diagnoses on day 1 (24% vs 14%; p =.003) and diagnostic workups being completed on day 1 (10% vs 3%; p <.001). The intervention group had more laboratory tests done (50.0 [interquartile range (IQR) 39.0–69.0] vs 43.0 [IQR 31.0–68.5]; p <.001). Otherwise, there were no differences between the groups. Conclusions: Pre-visit testing did not lead to a shorter overall time to diagnosis. However, a greater proportion of patients had a correct diagnosis on the first day. Further studies should focus on customizing pre-visit laboratory panels, to improve their efficacy. Trial Registration: NL5009.

Published
2021

11. The Impact of a Standardized Pre-visit Laboratory Testing Panel in the Internal Medicine Outpatient Clinic: a Controlled 'On-Off' Trial

Author

MS Interne Geneeskunde, NVIC, CDL Staf Patiëntenzorg KC, Infection & Immunity, Epi Methoden Team 1, CDL Klinisch Chemici in opleiding, Circulatory Health, CDL Arcadia, CDL Upod, Centraal Diagnostisch Laboratorium, Vrijsen, B E L, Ten Berg, M J, Naaktgeboren, C A, Vis, J Y, Dijstelbloem, H M, Westerink, J, Dekker, D, Hoefer, I E, Haitjema, S, Hulsbergen-Veelken, C A R, van Solinge, W W, Kaasjager, H A H, MS Interne Geneeskunde, NVIC, CDL Staf Patiëntenzorg KC, Infection & Immunity, Epi Methoden Team 1, CDL Klinisch Chemici in opleiding, Circulatory Health, CDL Arcadia, CDL Upod, Centraal Diagnostisch Laboratorium, Vrijsen, B E L, Ten Berg, M J, Naaktgeboren, C A, Vis, J Y, Dijstelbloem, H M, Westerink, J, Dekker, D, Hoefer, I E, Haitjema, S, Hulsbergen-Veelken, C A R, van Solinge, W W, and Kaasjager, H A H

Published
2021

19. On illustrating Carnot's general proposition by means of reversible Stirling engines.

Author

Naaktgeboren, C, Beck, KAÉ, and Lafay, J-MS

Subjects
*HEAT engines, *SECOND law of thermodynamics, *STIRLING engines, *PROPERTIES of fluids, *WORKING fluids, *WATER temperature
Abstract

Carnot's general proposition, also referred to as one of Carnot's principles, states that the work producing potential of heat—harvested by reversible heat engines—is independent of the working fluid and of engine internal details, being only a function of the temperatures of the reservoirs with which the engine exchanges heat. This concept, usually presented in introductory thermodynamics courses to ME students in the context of the second law of thermodynamics before entropy is introduced, is customarily proven by contradiction, i.e., by a violation of the second law, using second law concepts and abstractions such as 'thermal reservoirs' and 'reversible engines', without concrete examples, even though Carnot's proposition mentions concrete things such as working fluids and engine internal details. This work proposes to document the usage of different reversible Stirling engine models that take the engine arrangement down to engine constructive parameters, crankshaft angles, and the like, as well as fluid properties into account towards illustrating the validity of Carnot's general proposition without using entropy. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

21. Ketonuria is not associated with hyperemesis gravidarum disease severity

Author

Koot, M.H., Grooten, I.J., Vd Post, J.A.M., Bais, J.M., Ris-Stalpers, C., Naaktgeboren, C., Heidema, W.M., Roseboom, T.J., Painter, R.C., Koot, M.H., Grooten, I.J., Vd Post, J.A.M., Bais, J.M., Ris-Stalpers, C., Naaktgeboren, C., Heidema, W.M., Roseboom, T.J., and Painter, R.C.

Abstract

Contains fulltext : 226778.pdf (Publisher’s version ) (Closed access)

Published
2020

22. Maternal Sildenafil vs Placebo in Pregnant Women With Severe Early-Onset Fetal Growth Restriction: A Randomized Clinical Trial

Author

Pels, A. (Anouk), Derks, J.B. (Jan), Elvan-Taşpinar, A. (Ayten), van Drongelen, J. (Joris), de Boer, M. (Marjon), Duvekot, J.J. (Hans), van Laar, J. (Judith), Eyck, J. (Jim) van, Al-Nasiry, S. (Salwan), Sueters, M. (Marieke), Post, M. (Marinka), Onland, W. (Wes), Wassenaer-Leemhuis, A.G. (Aleid) van, Naaktgeboren, C. (Christiana), Jakobsen, J.C. (Janus C.), Gluud, C. (Christian), Duijnhoven, R.G. (Ruben), Lely, T. (Titia), Gordijn, S. (Sanne), Ganzevoort, W. (Wessel), Pels, A. (Anouk), Derks, J.B. (Jan), Elvan-Taşpinar, A. (Ayten), van Drongelen, J. (Joris), de Boer, M. (Marjon), Duvekot, J.J. (Hans), van Laar, J. (Judith), Eyck, J. (Jim) van, Al-Nasiry, S. (Salwan), Sueters, M. (Marieke), Post, M. (Marinka), Onland, W. (Wes), Wassenaer-Leemhuis, A.G. (Aleid) van, Naaktgeboren, C. (Christiana), Jakobsen, J.C. (Janus C.), Gluud, C. (Christian), Duijnhoven, R.G. (Ruben), Lely, T. (Titia), Gordijn, S. (Sanne), and Ganzevoort, W. (Wessel)

Abstract

Importance: Severe early onset fetal growth restriction caused by placental dysfunction leads to high rates of perinatal mortality and neonatal morbidity. The phosphodiesterase 5 inhibitor, sildenafil, inhibits cyclic guanosine monophosphate hydrolysis, thereby activating the effects of nitric oxide, and might improve uteroplacental function and subsequent perinatal outcomes. Objective: To determine whether sildenafil reduces perinatal mortality or major morbidity. Design, Setting, and Participants: This placebo-controlled randomized clinical trial was conducted at 10 tertiary referral centers and 1 general hospital in the Netherlands from January 20, 2015, to July 16, 2018. Participants included pregnant women between 20 and 30 weeks of gestation with severe fetal growth restriction, defined as fetal abdominal circumference below the third percentile or estimated fetal weight below the fifth percentile combined with Dopplers measurements outside reference ranges or a maternal hypertensive disorder. The trial was stopped early owing to safety concerns on July 19, 2018, whereas benefit on the primary outcome was unlikely. Data were analyzed from January 20, 2015, to January 18, 2019. The prespecified primary analysis was an intention-to-treat analysis including all randomized participants. Interventions: Participants were randomized to sildenafil, 25 mg, 3 times a day vs placebo. Main Outcomes and Measures: The primary outcome was a composite of perinatal mortality or major neonatal morbidity until hospital discharge. Results: Out of 360 planned participants, a total of 216 pregnant women were included, with 108 women randomized to sildenafil (median gestational age at randomization, 24 weeks 5 days [interquartile range, 23 weeks 3 days to 25 weeks 5 days]; mean [SD] estimated fetal weight, 458 [160] g) and 108 women randomized to placebo (median gestational age, 25 weeks 0 days [interquartile range, 22 weeks 5 days to 26 weeks 3 days]; mean [SD] estimated fetal weig

Published
2020
Full Text
View/download PDF

24. Inappropriate laboratory testing in internal medicine inpatients: Prevalence, causes and interventions

Author

NVIC, MS Interne Geneeskunde, JC onderzoeksprogramma Methodologie, MS Infectieziekten, Centraal Diagnostisch Laboratorium, Circulatory Health, CDL Staf Patiëntenzorg KC, Infection & Immunity, Vrijsen, B. E.L., Naaktgeboren, C. A., Vos, L. M., van Solinge, W. W., Kaasjager, H. A.H., ten Berg, M. J., NVIC, MS Interne Geneeskunde, JC onderzoeksprogramma Methodologie, MS Infectieziekten, Centraal Diagnostisch Laboratorium, Circulatory Health, CDL Staf Patiëntenzorg KC, Infection & Immunity, Vrijsen, B. E.L., Naaktgeboren, C. A., Vos, L. M., van Solinge, W. W., Kaasjager, H. A.H., and ten Berg, M. J.

Published
2020

25. Maternal Sildenafil vs Placebo in Pregnant Women With Severe Early-Onset Fetal Growth Restriction A Randomized Clinical Trial

Author

Pels, A, Derks, J, Elvan-Taspinar, A, van Drongelen, J, Boer, M, Duvekot, J.J., van Laar, JAM, Eyck, J, Al-Nasiry, S, Sueters, M, Verhoef-Post, M, Onland, W, van Wassenaer-Leemhuis, A, Naaktgeboren, C, Jakobsen, JC, Gluud, C, Duijnhoven, RG, Lely, T, Gordijn, S, Ganzevoort, W, Pels, A, Derks, J, Elvan-Taspinar, A, van Drongelen, J, Boer, M, Duvekot, J.J., van Laar, JAM, Eyck, J, Al-Nasiry, S, Sueters, M, Verhoef-Post, M, Onland, W, van Wassenaer-Leemhuis, A, Naaktgeboren, C, Jakobsen, JC, Gluud, C, Duijnhoven, RG, Lely, T, Gordijn, S, and Ganzevoort, W

Published
2020

26. Barriers and facilitators to reduce low-value care: a qualitative evidence synthesis

Author

Epi Methoden Team 1, Epi Methoden Team 5, Other research (not in main researchprogram), JC onderzoeksprogramma Methodologie, van Dulmen, S A, Naaktgeboren, C A, Heus, Pauline, Verkerk, Eva W, Weenink, J, Kool, Rudolf Bertijn, Hooft, Lotty, Epi Methoden Team 1, Epi Methoden Team 5, Other research (not in main researchprogram), JC onderzoeksprogramma Methodologie, van Dulmen, S A, Naaktgeboren, C A, Heus, Pauline, Verkerk, Eva W, Weenink, J, Kool, Rudolf Bertijn, and Hooft, Lotty

Published
2020

27. The effects of nifedipine and atosiban on perinatal brain injury: a secondary analysis of the APOSTEL III trial

Author

Nijman, T. A. J., Goedhart, M. M., Naaktgeboren, C. N., de Haan, T. R., Vijlbrief, D. C., Mol, B. W., Benders, M. J. N., Franx, A., Oudijk, M. A., Neonatology, Amsterdam Reproduction & Development (AR&D), Obstetrics and Gynaecology, and Amsterdam Gastroenterology Endocrinology Metabolism

Abstract

Brain injury in prematurely born neonates is strongly associated with poor neurodevelopmental outcome. The aim of our study is to evaluate if nifedipine reduces overall brain injury compared to atosiban in women with threatened preterm birth. We performed a secondary analysis of the APOSTEL III-trial (Dutch Clinical Trial Registry, number NTR2947). This was a randomized clinical trial that allocated women with threatened preterm labor between 25-34 weeks of gestation to nifedipine or atosiban. For this secondary analysis, we included women delivering at ≤ 32 weeks of gestational age in the two main contributing centers. The primary outcome was the presence of brain injury. Brain injury was defined as the existence of abnormalities on ultrasound investigation, it was divided into mild and severe brain injury. To evaluate type and severity of brain injury, all neonatal ultrasounds made during neonatal intensive care admission and medium care admission were analyzed. A sensitivity analysis assessing differences in baseline or known risk factors for brain injury, was performed to test the robustness of our results. We studied 117 neonates, born from 102 women, of which 51 neonates had been exposed to nifedipine and 66 to atosiban. Brain injury was observed in 22 neonates (43.1%) in the nifedipine group and in 37 (56.1%) neonates in the atosiban (OR 0.60; 95% CI: 0.29-1.24). Mild brain injury was comparable between nifedipine (33.3%) and atosiban (48.5%, OR 0.53; 95% CI 0.25-1.13). Severe brain injury was also comparable between the groups, 9.8% for nifedipine and 7.6% for atosiban (OR 1.33; 95% CI 0.36-4.85). Intraventricular hemorrhage (≥ grade I) was most frequently seen; 18 neonates (35.3%) in the nifedipine group versus 25 neonates (37.9%) in the atosiban group (OR 0.90; 95% CI 0.42-1.91). The sensitivity analysis, with adjustment for maternal age and gestational age at randomization, showed no statistical difference of brain injury (OR 0.58; 95% CI 0.27-1.27). In children born before 32 weeks after the use of tocolytics, the prevalence of brain injury was high. No significant differences were found between nifedipine and atosiban in terms of overall brain injury. However, as this study was a secondary analysis of the APOSTEL III trial, it was underpowered for brain injury, as the latter was not the primary outcome of APOSTEL III

Published
2018

28. Exploring the value of routinely measured hematology parameters for identification of elderly patients at high risk of death at the Emergency Department

Author

Bindraban, R. S., ten Berg, M. J., Haitjema, S., Hoefer, I. E., de Regt, M., Kramer, M. H. H., van Solinge, W. W., Nanayakkara, P. W. B., Naaktgeboren, C. A., Internal medicine, APH - Health Behaviors & Chronic Diseases, CCA - Imaging and biomarkers, VU University medical center, APH - Digital Health, APH - Quality of Care, ACS - Diabetes & metabolism, and Academic Medical Center

Subjects
humanities
Abstract

Of the warning scores in use for recognition of high-risk patients at the Emergency Department (ED), few incorporate laboratory results. Although hematological characteristics have shown prognostic value in small studies, large studies in elderly ED populations are lacking. We studied the association between blood cell and platelet counts and characteristics as well as C-reactive protein (CRP) at ED presentation with mortality in non-multitrauma patients ≥ 65 years. Comparison between survivors and non-survivors showed small, significant differences with AUROCs ranging between 56.6% and 65.2% for 30-day mortality. Combining parameters yielded an evident improvement (AUROC of 70.4%). Efforts should be pursued to study the added value of hematological parameters on top of clinical data when assessing patient risk.

Published
2018

29. Erratum to:Methods for evaluating medical tests and biomarkers

Author

Gopalakrishna, G, Langendam, M, Scholten, R, Bossuyt, P, Leeflang, M, Noel-Storr, A, Thomas, J, Marshall, I, Wallace, B, Whiting, P, Davenport, C, GopalaKrishna, G, De Salis, I, Mallett, S, Wolff, R, Riley, R, Westwood, M, Kleinen, J, Collins, G, Reitsma, H, Moons, K, Zapf, A, Hoyer, A, Kramer, K, Kuss, O, Ensor, J, Deeks, JJ, Martin, EC, Riley, RD, Rücker, G, Steinhauser, S, Schumacher, M, Snell, K, Willis, B, Debray, T, Deeks, J, Di Ruffano, LF, Taylor-Phillips, S, Hyde, C, Taylor, SA, Batnagar, G, STREAMLINE COLON Investigators, STREAMLINE LUNG Investigators, METRIC Investigators, Seedat, F, Clarke, A, Byron, S, Nixon, F, Albrow, R, Walker, T, Deakin, C, Zhelev, Z, Hunt, H, Yang, Y, Abel, L, Buchanan, J, Fanshawe, T, Shinkins, B, Wynants, L, Verbakel, J, Van Huffel, S, Timmerman, D, Van Calster, B, Zwinderman, A, Oke, J, O'Sullivan, J, Perera, R, Nicholson, B, Bromley, HL, Roberts, TE, Francis, A, Petrie, D, Mann, GB, Malottki, K, Smith, H, Billingham, L, Sitch, A, Gerke, O, Holm-Vilstrup, M, Segtnan, EA, Halekoh, U, Høilund-Carlsen, PF, Francq, BG, Dinnes, J, Parkes, J, Gregory, W, Hewison, J, Altman, D, Rosenberg, W, Selby, P, Asselineau, J, Perez, P, Paye, A, Bessede, E, Proust-Lima, C, Naaktgeboren, C, De Groot, J, Rutjes, A, Reitsma, J, Ogundimu, E, Cook, J, Le Manach, Y, Vergouwe, Y, Pajouheshnia, R, Groenwold, R, Peelen, L, Nieboer, D, De Cock, B, Pencina, MJ, Steyerberg, EW, Cooper, J, Parsons, N, Stinton, C, Smith, S, Dickens, A, Jordan, R, Enocson, A, Fitzmaurice, D, Adab, P, Boachie, C, Vidmar, G, Freeman, K, Connock, M, Court, R, Moons, C, Harris, J, Mumford, A, Plummer, Z, Lee, K, Reeves, B, Rogers, C, Verheyden, V, Angelini, GD, Murphy, GJ, Huddy, J, Ni, M, Good, K, Cooke, G, Hanna, G, Ma, J, Moons, KGMC, De Groot, JAH, Altman, DG, Reitsma, JB, Collins, GS, Moons, KGM, Kamarudin, AN, Kolamunnage-Dona, R, Cox, T, Borsci, S, Pérez, T, Pardo, MC, Candela-Toha, A, Muriel, A, Zamora, J, Sanghera, S, Mohiuddin, S, Martin, R, Donovan, J, Coast, J, Seo, MK, Cairns, J, Mitchell, E, Smith, A, Wright, J, Hall, P, Messenger, M, Calder, N, Wickramasekera, N, Vinall-Collier, K, Lewington, A, Damen, J, Cairns, D, Hutchinson, M, Sturgeon, C, Mitchel, L, Kift, R, Christakoudi, S, Rungall, M, Mobillo, P, Montero, R, Tsui, T-L, Kon, SP, Tucker, B, Sacks, S, Farmer, C, Strom, T, Chowdhury, P, Rebollo-Mesa, I, Hernandez-Fuentes, M, Damen, JAAG, Debray, TPA, Heus, P, Hooft, L, Scholten, RJPM, Schuit, E, Tzoulaki, I, Lassale, CM, Siontis, GCM, Chiocchia, V, Roberts, C, Schlüssel, MM, Gerry, S, Black, JA, Van der Schouw, YT, Peelen, LM, Spence, G, McCartney, D, Van den Bruel, A, Lasserson, D, Hayward, G, Vach, W, De Jong, A, Burggraaff, C, Hoekstra, O, Zijlstra, J, De Vet, H, Graziadio, S, Allen, J, Johnston, L, O'Leary, R, Power, M, Johnson, L, Waters, R, Simpson, J, Fanshawe, TR, Phillips, P, Plumb, A, Helbren, E, Halligan, S, Gale, A, Sekula, P, Sauerbrei, W, Forman, JR, Dutton, SJ, Takwoingi, Y, Hensor, EM, Nichols, TE, Kempf, E, Porcher, R, De Beyer, J, Hopewell, S, Dennis, J, Shields, B, Jones, A, Henley, W, Pearson, E, Hattersley, A, MASTERMIND consortium, Scheibler, F, Rummer, A, Sturtz, S, Großelfinger, R, Banister, K, Ramsay, C, Azuara-Blanco, A, Burr, J, Kumarasamy, M, Bourne, R, Uchegbu, I, Murphy, J, Carter, A, Marti, J, Eatock, J, Robotham, J, Dudareva, M, Gilchrist, M, Holmes, A, Monaghan, P, Lord, S, StJohn, A, Sandberg, S, Cobbaert, C, Lennartz, L, Verhagen-Kamerbeek, W, Ebert, C, Horvath, A, Test Evaluation Working Group of the European Federation of Clinical Chemistry and Laboratory Medicine, Jenniskens, K, Peters, J, Grigore, B, Ukoumunne, O, Levis, B, Benedetti, A, Levis, AW, Ioannidis, JPA, Shrier, I, Cuijpers, P, Gilbody, S, Kloda, LA, McMillan, D, Patten, SB, Steele, RJ, Ziegelstein, RC, Bombardier, CH, Osório, FDL, Fann, JR, Gjerdingen, D, Lamers, F, Lotrakul, M, Loureiro, SR, Löwe, B, Shaaban, J, Stafford, L, Van Weert, HCPM, Whooley, MA, Williams, LS, Wittkampf, KA, Yeung, AS, Thombs, BD, Cooper, C, Nieto, T, Smith, C, Tucker, O, Dretzke, J, Beggs, A, Rai, N, Bayliss, S, Stevens, S, Mallet, S, Sundar, S, Hall, E, Porta, N, Estelles, DL, De Bono, J, CTC-STOP protocol development group, and National Institute for Health Research

Subjects
medicine.medical_specialty, Astrophysics::High Energy Astrophysical Phenomena, MEDLINE, 030204 cardiovascular system & hematology, BTC (Bristol Trials Centre), MASTERMIND consortium, 03 medical and health sciences, 0302 clinical medicine, medicine, 030212 general & internal medicine, Intensive care medicine, CTC-STOP protocol development group, lcsh:R5-920, business.industry, Test Evaluation Working Group of the European Federation of Clinical Chemistry and Laboratory Medicine, Published Erratum, STREAMLINE COLON Investigators, 3. Good health, STREAMLINE LUNG Investigators, Centre for Surgical Research, Family medicine, METRIC Investigators, High Energy Physics::Experiment, Erratum, business, lcsh:Medicine (General)
Abstract

[This corrects the article DOI: 10.1186/s41512-016-0001-y.].

Published
2017
Full Text
View/download PDF

31. Unicorns: immortal and extinct

Author

Naaktgeboren, C.

Subjects
Animals, Mythical -- Myths and legends, Unicorns -- Myths and legends, Advertising, marketing and public relations, Business, Pharmaceuticals and cosmetics industries
Published
1990

32. Effects of tocolysis with nifedipine or atosiban on child outcome: follow-up of the APOSTEL III trial.

Author

Winden, TMS, Klumper, J, Kleinrouweler, CE, Tichelaar, MA, Naaktgeboren, CA, Nijman, TA, Baar, AL, Wassenaer‐Leemhuis, AG, Roseboom, TJ, van't Hooft, J, Roos, C, Mol, BW, Pajkrt, E, Oudijk, MA, van Winden, Tms, Kleinrouweler, C E, Tichelaar, M A, Naaktgeboren, C A, Nijman, T A, and van Baar, A L

Subjects
RANDOMIZED controlled trials, PREMATURE labor, NEURAL development, NIFEDIPINE, EXECUTIVE function, RESEARCH, PREMATURE infants, RESEARCH methodology, TOCOLYTIC agents, HEALTH status indicators, EVALUATION research, MEDICAL cooperation, BEHAVIOR disorders in children, COMPARATIVE studies, HUMAN reproductive technology, RESEARCH funding, PITUITARY hormones, LONGITUDINAL method
Abstract

Objective: To compare the long-term effects of tocolysis with nifedipine or atosiban on child outcome at age 2.5-5.5 years.Design: The APOSTEL III trial was a multicentre randomised controlled trial that compared tocolysis with nifedipine or atosiban in 503 women with threatened preterm birth. Neonatal outcomes did not differ between both treatment arms, except for a higher incidence of intubation in the atosiban group.Methods: Parents were asked to complete four questionnaires regarding neurodevelopment, executive function, behaviour problems and general health.Main Outcome Measures: The main long-term outcome measure was a composite of abnormal development at the age of 2.5-5.5 years.Results: Of the 426 women eligible for follow-up, 196 (46%) parents returned the questionnaires for 115 children in the nifedipine group and 110 children in the atosiban group. Abnormal development occurred in 32 children (30%) in the nifedipine group and in 38 children (38%) in the atosiban group (OR 0.74, 95% CI 0.41-1.34). The separate outcomes for neurodevelopment, executive function, behaviour, and general health showed no significant differences between the groups. Sensitivity analysis for all children of the APOSTEL III trial, including a comparison of deceased children, resulted in a higher rate of healthy survival in the nifedipine group (64 versus 54%), but there was no significant difference in the overall mortality rate (5.4 versus 2.7%). There were no significant subgroup effects.Conclusion: Outcomes on broad child neurodevelopment, executive function, behaviour and general health were comparable in both groups. Neither nifedipine nor atosiban can be considered as the preferred treatment for women with threatened preterm birth.Tweetable Abstract: Nifedipine- and atosiban-exposed children had comparable long-term outcomes, including neurodevelopment, executive function and behaviour. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

35. Effect of nifedipine and atosiban on perinatal brain injury: secondary analysis of the APOSTEL-III trial

Author

MS Verloskunde, Epi Methoden Team 1, JC onderzoeksprogramma Methodologie, MS Neonatologie, Child Health, Brain, Circulatory Health, Nijman, T. A.J., Goedhart, M. M., Naaktgeboren, C. N., de Haan, T. R., Vijlbrief, D. C., Mol, B. W., Benders, M. J.N., Franx, A., Oudijk, M. A., MS Verloskunde, Epi Methoden Team 1, JC onderzoeksprogramma Methodologie, MS Neonatologie, Child Health, Brain, Circulatory Health, Nijman, T. A.J., Goedhart, M. M., Naaktgeboren, C. N., de Haan, T. R., Vijlbrief, D. C., Mol, B. W., Benders, M. J.N., Franx, A., and Oudijk, M. A.

Published
2018

36. DeCIDE study: Impact of diagnostic criteria for gestational diabetes mellitus on prevalence and adverse pregnancy outcomes in the Netherlands

Author

Child Health, MS Verloskunde, Epi Methoden Team 1, JC onderzoeksprogramma Methodologie, Zijlmans, A., De Wit, L., Naaktgeboren, C., Painter, R., De Vries, H., Van Rijn, B., Child Health, MS Verloskunde, Epi Methoden Team 1, JC onderzoeksprogramma Methodologie, Zijlmans, A., De Wit, L., Naaktgeboren, C., Painter, R., De Vries, H., and Van Rijn, B.

Published
2018

39. MisoREST : surgical versus expectant management in women with an incomplete evacuation of the uterus after misoprostol treatment for miscarriage: a randomized controlled trial

Author

Lemmers, M, Verschoor, M A C, Oude Rengerink, K, Naaktgeboren, C, Opmeer, B C, Bossuyt, P M, Huirne, J A F, Janssen, C A H, Radder, C, Klinkert, E R, Langenveld, J, Catshoek, R, Van der Voet, L, Siemens, F, Geomini, P, Van Hooff, M H, Van der Ploeg, J M, Coppus, S F P J, Ankum, W M, Mol, B W J, and MisoREST study group

Subjects
surgery, uterus, miscarriage, Journal Article, abortion, expectant management
Abstract

STUDY QUESTION: Is curettage more effective than expectant management in case of an incomplete evacuation after misoprostol treatment for first trimester miscarriage? SUMMARY ANSWER: Curettage leads to a higher chance of complete evacuation but expectant management is successful in at least 76% of women with an incomplete evacuation of the uterus after misoprostol treatment for first trimester miscarriage. WHAT IS KNOWN ALREADY: In 5-50% of the women treated with misoprostol, there is a suspicion of incomplete evacuation of the uterus on sonography. Although these women generally have minor symptoms, such a finding often leads to additional curettage. STUDY DESIGN, SIZE, DURATION: From June 2012 until July 2014, we conducted a nationwide multicenter randomized controlled trial (RCT). Women who had had primary misoprostol treatment for miscarriage with sonographic evidence of incomplete evacuation of the uterus were randomly allocated to either curettage or expectant management (1:1), using a web-based application. PARTICIPANTS/MATERIALS, SETTING, METHODS: We included 59 women in 27 hospitals; 30 were allocated to curettage and 29 were allocated to expectant management. A successful outcome was defined as sonographic finding of an empty uterus 6 weeks after randomization. MAIN RESULTS AND THE ROLE OF CHANCE: Baseline characteristics of both groups were comparable. Empty uterus on sonography or uneventful clinical follow-up was seen in 29/30 women (97%) allocated to curettage compared with 22/29 women (76%) allocated to expectant management (RR 1.3, 95% CI 1.03-1.6) with complication rates of 10% versus 10%, respectively (RR 0.97, 95% CI 0.21-4.4). In the group allocated to curettage, no woman required re-curettage, while two women (6.7%) underwent hysteroscopy (for other or unknown reasons). In the women allocated to expectant management, curettage was performed in four women (13.8%) and three women (10.3%) underwent hysteroscopy. LIMITATIONS, REASONS FOR CAUTION: Due to a strong patient preference, mainly for expectant management, the targeted sample size could not be included and the trial was stopped prematurely. WIDER IMPLICATIONS OF THE FINDINGS: In women suspected of incomplete evacuation of the uterus after misoprostol, curettage is more effective than expectant management. However, expectant management is equally safe and prevents curettage for most of the women. This finding could further restrain the use of curettage in the treatment of first trimester miscarriage. STUDY FUNDING/COMPETING INTERESTS: This study was funded by ZonMw, a Dutch organization for Health Research and Development, project number 80-82310-97-12066. There were no conflicts of interests. TRIAL REGISTRATION NUMBER: Dutch Trial Register NTR3310, http://www.trialregister.nl TRIAL REGISTRATION DATE: 27 February 2012. DATE OF FIRST PATIENT'S ENROLMENT: 12 June 2012.

Published
2016

41. Low dose aspirin in the prevention of recurrent spontaneous preterm labour - the APRIL study: a multicenter randomized placebo controlled trial

Author

Visser, L de, Boer, M.A. de, Groot, C.J. de, Nijman, T.A., Hemels, M.A.C., Bloemenkamp, K.W., Bosmans, J.E., Kok, M. de, Laar, J.O.E.H. van, Sueters, M., Scheepers, H., Drongelen, J. van, Franssen, M.T., Sikkema, J.M., Duvekot, H.J., Bekker, M.N., Post, J.A. van der, Naaktgeboren, C., Mol, B.W., Oudijk, M.A., Visser, L de, Boer, M.A. de, Groot, C.J. de, Nijman, T.A., Hemels, M.A.C., Bloemenkamp, K.W., Bosmans, J.E., Kok, M. de, Laar, J.O.E.H. van, Sueters, M., Scheepers, H., Drongelen, J. van, Franssen, M.T., Sikkema, J.M., Duvekot, H.J., Bekker, M.N., Post, J.A. van der, Naaktgeboren, C., Mol, B.W., and Oudijk, M.A.

Abstract

Contains fulltext : 177805.pdf (publisher's version ) (Open Access), BACKGROUND: Preterm birth (birth before 37 weeks of gestation) is a major problem in obstetrics and affects an estimated 15 million pregnancies worldwide annually. A history of previous preterm birth is the strongest risk factor for preterm birth, and recurrent spontaneous preterm birth affects more than 2.5 million pregnancies each year. A recent meta-analysis showed possible benefits of the use of low dose aspirin in the prevention of recurrent spontaneous preterm birth. We will assess the (cost-)effectiveness of low dose aspirin in comparison with placebo in the prevention of recurrent spontaneous preterm birth in a randomized clinical trial. METHODS/DESIGN: Women with a singleton pregnancy and a history of spontaneous preterm birth in a singleton pregnancy (22-37 weeks of gestation) will be asked to participate in a multicenter, randomized, double blinded, placebo controlled trial. Women will be randomized to low dose aspirin (80 mg once daily) or placebo, initiated from 8 to 16 weeks up to maximal 36 weeks of gestation. The primary outcome measure will be preterm birth, defined as birth at a gestational age (GA) < 37 weeks. Secondary outcomes will be a composite of adverse neonatal outcome and maternal outcomes, including subgroups of prematurity, as well as intrauterine growth restriction (IUGR) and costs from a healthcare perspective. Preterm birth will be analyzed as a group, as well as separately for spontaneous or indicated onset. Analysis will be performed by intention to treat. In total, 406 pregnant women have to be randomized to show a reduction of 35% in preterm birth from 36 to 23%. If aspirin is effective in preventing preterm birth, we expect that there will be cost savings, because of the low costs of aspirin. To evaluate this, a cost-effectiveness analysis will be performed comparing preventive treatment with aspirin with placebo. DISCUSSION: This trial will provide evidence as to whether or not low dose aspirin is (cost-) effective in reducing r

Published
2017

42. Early enteral tube feeding in optimizing treatment of hyperemesis gravidarum: the Maternal and Offspring outcomes after Treatment of HyperEmesis by Refeeding (MOTHER) randomized controlled trial

Author

Grooten, I.J., Koot, M.H., Post, J.A. van der, Bais, J.M., Ris-Stalpers, C., Naaktgeboren, C., Bremer, H.A., Ham, D.P. van der, Heidema, W.M., Huisjes, A., Kleiverda, G., Kuppens, S., Laar, J.O.E.H. van, Langenveld, J., Made, F. van der, Pampus, M.G. van, Papatsonis, D., Pelinck, M.J., Pernet, P.J., Rheenen, L. van, Rijnders, R.J., Scheepers, H.C., Vogelvang, T.E., Mol, B.W., Roseboom, T.J., Painter, R.C., Grooten, I.J., Koot, M.H., Post, J.A. van der, Bais, J.M., Ris-Stalpers, C., Naaktgeboren, C., Bremer, H.A., Ham, D.P. van der, Heidema, W.M., Huisjes, A., Kleiverda, G., Kuppens, S., Laar, J.O.E.H. van, Langenveld, J., Made, F. van der, Pampus, M.G. van, Papatsonis, D., Pelinck, M.J., Pernet, P.J., Rheenen, L. van, Rijnders, R.J., Scheepers, H.C., Vogelvang, T.E., Mol, B.W., Roseboom, T.J., and Painter, R.C.

Abstract

Item does not contain fulltext, Background: Hyperemesis gravidarum (HG) leads to dehydration, poor nutritional intake, and weight loss. HG has been associated with adverse pregnancy outcomes such as low birth weight. Information about the potential effectiveness of treatments for HG is limited.Objective: We hypothesized that in women with HG, early enteral tube feeding in addition to standard care improves birth weight.Design: We performed a multicenter, open-label randomized controlled trial [Maternal and Offspring outcomes after Treatment of HyperEmesis by Refeeding (MOTHER)] in 19 hospitals in the Netherlands. A total of 116 women hospitalized for HG between 5 and 20 wk of gestation were randomly allocated to enteral tube feeding for >/=7 d in addition to standard care with intravenous rehydration and antiemetic treatment or to standard care alone. Women were encouraged to continue tube feeding at home. On the basis of our power calculation, a sample size of 120 women was anticipated. Analyses were performed according to the intention-to-treat principle.Results: Between October 2014 and March 2016 we randomly allocated 59 women to enteral tube feeding and 57 women to standard care. The mean +/- SD birth weight was 3160 +/- 770 g in the enteral tube feeding group compared with 3200 +/- 680 g in the standard care group (mean difference: -40 g, 95% CI: -230, 310 g). Secondary outcomes, including maternal weight gain, duration of hospital stay, readmission rate, nausea and vomiting symptoms, decrease in quality of life, psychological distress, prematurity, and small-for-gestational-age, also were comparable. Of the women allocated to enteral tube feeding, 28 (47%) were treated according to protocol. Enteral tube feeding was discontinued within 7 d of placement in the remaining women, primarily because of its adverse effects (34%).Conclusions: In women with HG, early enteral tube feeding does not improve birth weight or secondary outcomes. Many women discontinued tube feeding because of discomfort

Published
2017

43. Low dose aspirin in the prevention of recurrent spontaneous preterm labour - the APRIL study: A multicenter randomized placebo controlled trial

Author

Visser, L. (Laura), de Boer, M.A. (Marjon A.), Groot, C.J.M. (Christianne) de, Nijman, T.A.J. (Tobias A.J.), Hemels, M.A.C. (Marieke A.C.), Bloemenkamp, K.W.M. (Kitty), Bosmans, J.E. (Judith), Kok, M. (Marjolein), van Laar, J.O. (Judith O.), Sueters, M. (Marieke), Scheepers, H.C.J. (Hubertina), van Drongelen, J. (Joris), Franssen, M.T.M. (Maureen), Sikkema, J.M. (J. Marko), Duvekot, J.J. (Hans), Bekker, M.N. (Mireille), Post, J.A.M. (Joris) van der, Naaktgeboren, C. (Christiana), Mol, B.W.J. (Ben), Oudijk, M.A. (Martijn), Visser, L. (Laura), de Boer, M.A. (Marjon A.), Groot, C.J.M. (Christianne) de, Nijman, T.A.J. (Tobias A.J.), Hemels, M.A.C. (Marieke A.C.), Bloemenkamp, K.W.M. (Kitty), Bosmans, J.E. (Judith), Kok, M. (Marjolein), van Laar, J.O. (Judith O.), Sueters, M. (Marieke), Scheepers, H.C.J. (Hubertina), van Drongelen, J. (Joris), Franssen, M.T.M. (Maureen), Sikkema, J.M. (J. Marko), Duvekot, J.J. (Hans), Bekker, M.N. (Mireille), Post, J.A.M. (Joris) van der, Naaktgeboren, C. (Christiana), Mol, B.W.J. (Ben), and Oudijk, M.A. (Martijn)

Abstract

Background: Preterm birth (birth before 37 weeks of gestation) is a major problem in obstetrics and affects an estimated 15 million pregnancies worldwide annually. A history of previous preterm birth is the strongest risk factor for preterm birth, and recurrent spontaneous preterm birth affects more than 2.5 million pregnancies each year. A recent meta-analysis showed possible benefits of the use of low dose aspirin in the prevention of recurrent spontaneous preterm birth. We will assess the (cost-)effectiveness of low dose aspirin in comparison with placebo in the prevention of recurrent spontaneous preterm birth in a randomized clinical trial. Methods/design: Women with a singleton pregnancy and a history of spontaneous preterm birth in a singleton pregnancy (22-37 weeks of gestation) will be asked to participate in a multicenter, randomized, double blinded, placebo controlled trial. Women will be randomized to low dose aspirin (80 mg once daily) or placebo, initiated from 8 to 16 weeks up to maximal 36 weeks of gestation. The primary outcome measure will be preterm birth, defined as birth at a gestational age (GA) < 37 weeks. Secondary outcomes will be a composite of adverse neonatal outcome and maternal outcomes, including subgroups of prematurity, as well as intrauterine growth restriction (IUGR) and costs from a healthcare perspective. Preterm birth will be analyzed as a group, as well as separately for spontaneous or indicated onset. Analysis will be performed by intention to treat. In total, 406 pregnant women have to be randomized to show a reduction of 35% in preterm birth from 36 to 23%. If aspirin is effective in preventing preterm birth, we expect that there will be cost savings, because of the low costs of aspirin. To evaluate this, a cost-effectiveness analysis will be performed comparing preventive treatment with aspirin with placebo. Discussion: This trial will provide evidence as to whether or not low dose aspirin is (cost-) effective in reducing r

Published
2017
Full Text
View/download PDF

44. Early enteral tube feeding in optimizing treatment of hyperemesis gravidarum: The Maternal and Offspring outcomes after Treatment of HyperEmesis by Refeeding (MOTHER) randomized controlled trial

Author

Grooten, I.J. (Iris J.), Koot, M.H. (Marjette H.), Post, J.A.M. (Joris) van der, Bais, A.G. (Aagje), Ris-stalpers, C. (Carrie), Naaktgeboren, C. (Christiana), Bremer, H.A. (Henk), Ham, D.P. (David) van der, Heidema, W.M. (Wieteke M.), Huisjes, A. (Anjoke), Kleiverda, G. (Gunilla), Kuppens, A.H. (An), Van Laar, J.O.E.H. (Judith O.E.H.), Langenveld, J. (Josje), Van Der Made, F. (Flip), Pampus, M. (Mariëlle) van, Papatsonis, D.N.M. (Dimitri), Pelinck, M.-J. (Marie-José), Pernet, P.J.M. (Paula), Van Rheenen, L. (Leonie), Rijnders, R.J.P. (Robbert), Scheepers, H.C.J. (Hubertina), Vogelvang, T.E. (Tatjana E.), Mol, B.W.J. (Ben), Roseboom, T.J. (Tessa), Painter, R.C. (Rebecca C.), Grooten, I.J. (Iris J.), Koot, M.H. (Marjette H.), Post, J.A.M. (Joris) van der, Bais, A.G. (Aagje), Ris-stalpers, C. (Carrie), Naaktgeboren, C. (Christiana), Bremer, H.A. (Henk), Ham, D.P. (David) van der, Heidema, W.M. (Wieteke M.), Huisjes, A. (Anjoke), Kleiverda, G. (Gunilla), Kuppens, A.H. (An), Van Laar, J.O.E.H. (Judith O.E.H.), Langenveld, J. (Josje), Van Der Made, F. (Flip), Pampus, M. (Mariëlle) van, Papatsonis, D.N.M. (Dimitri), Pelinck, M.-J. (Marie-José), Pernet, P.J.M. (Paula), Van Rheenen, L. (Leonie), Rijnders, R.J.P. (Robbert), Scheepers, H.C.J. (Hubertina), Vogelvang, T.E. (Tatjana E.), Mol, B.W.J. (Ben), Roseboom, T.J. (Tessa), and Painter, R.C. (Rebecca C.)

Abstract

Background: Hyperemesis gravidarum (HG) leads to dehydration, poor nutritional intake, and weight loss. HG has been associated with adverse pregnancy outcomes such as low birth weight. Information about the potential effectiveness of treatments for HG is limited. Objective: We hypothesized that in women with HG, early enteral tube feeding in addition to standard care improves birth weight. Design: We performed a multicenter, open-label randomized controlled trial [Maternal and Offspring outcomes after Treatment of HyperEmesis by Refeeding (MOTHER)] in 19 hospitals in the Netherlands. A total of 116 women hospitalized for HG between 5 and 20 wk of gestation were randomly allocated to enteral tube feeding for ≥7 d in addition to standard care with intravenous rehydration and antiemetic treatment or to standard care alone. Women were encouraged to continue tube feeding at home. On the basis of our power calculation, a sample size of 120 women was anticipated. Analyses were performed according to the intention-to-treat principle. Results: Between October 2014 and March 2016 we randomly allocated 59 women to enteral tube feeding and 57 women to standard care. The mean ± SD birth weight was 3160 ± 770 g in the enteral tube feeding group compared with 3200 ± 680 g in the standard care group (mean difference: -40 g, 95% CI: -230, 310 g). Secondary outcomes, including maternal weight gain, duration of hospital stay, readmission rate, nausea and vomiting symptoms, decrease in quality of life, psychological distress, prematurity, and small-for-gestationalage, also were comparable. Of the women allocated to enteral tube feeding, 28 (47%) were treated according to protocol. Enteral tube feeding was discontinued within 7 d of placement in the remaining women, primarily because of its adverse effects (34%). Conclusions: In women with HG, early enteral tube feeding does not improve birth weight or secondary outcomes. Many women discontinued tube feeding because of discomfort, sugge

Published
2017
Full Text
View/download PDF

45. MisoREST: Surgical versus expectant management in women with an incomplete evacuation of the uterus after misoprostol treatment for miscarriage: A cohort study

Author

Lemmers, M., Verschoor, M.A., Oude Rengerink, K., Naaktgeboren, C., Bossuyt, P.M., Huirne, J.A., Janssen, I.A.W., Radder, C., Klinkert, E.R., Langenveld, J., Voet, L. Van der, Siemens, F.F., Bongers, M.Y., Hooff, M.H. van, Ploeg, M., Coppus, S.F.P.J., Ankum, W.M., Mol, B.W., Lemmers, M., Verschoor, M.A., Oude Rengerink, K., Naaktgeboren, C., Bossuyt, P.M., Huirne, J.A., Janssen, I.A.W., Radder, C., Klinkert, E.R., Langenveld, J., Voet, L. Van der, Siemens, F.F., Bongers, M.Y., Hooff, M.H. van, Ploeg, M., Coppus, S.F.P.J., Ankum, W.M., and Mol, B.W.

Abstract

Item does not contain fulltext, OBJECTIVE: To assess the effectiveness of curettage versus expectant management in women with an incomplete evacuation of the uterus after misoprostol treatment for first trimester miscarriage. STUDY DESIGN: We conducted a multicenter cohort study alongside a randomized clinical trial (RCT) between June 2012 until July 2014. 27 Dutch hospitals participated. Women with an incomplete evacuation after misoprostol treatment for first trimester miscarriage who declined to participate in the RCT, received treatment of their preference; curettage (n=65) or expectant management (n=132). A successful outcome was defined as an empty uterus on sonography at six weeks or uneventful clinical follow-up. We furthermore assessed complication rate and (re)intervention rate RESULTS: Of the 197 women who declined to participate in the RCT, 65 preferred curettage and 132 expectant management. A successful outcome was observed in 62/65 women (95%) in the surgical group versus 112/132 women (85%) in the expectant group (RR 1.1, 95% CI 1.03-1.2), with complication rates of 6.2% versus 2.3%, respectively (RR 2.7, 95% CI 0.6-12). CONCLUSION: In women with an incomplete evacuation of the uterus after misoprostol treatment, expectant management is an effective and safe option. This finding could restrain the use of curettage in women that have used misoprostol in the treatment of first trimester miscarriage.

Published
2017

46. Erratum to: Methods for evaluating medical tests and biomarkers.

Author

Gopalakrishna, G, Langendam, M, Scholten, R, Bossuyt, P, Leeflang, M, Noel-Storr, A, Thomas, J, Marshall, I, Wallace, B, Whiting, P, Davenport, C, GopalaKrishna, G, de Salis, I, Mallett, S, Wolff, R, Riley, R, Westwood, M, Kleinen, J, Collins, G, Reitsma, H, Moons, K, Zapf, A, Hoyer, A, Kramer, K, Kuss, O, Ensor, J, Deeks, JJ, Martin, EC, Riley, RD, Rücker, G, Steinhauser, S, Schumacher, M, Snell, K, Willis, B, Debray, T, Deeks, J, di Ruffano, LF, Taylor-Phillips, S, Hyde, C, Taylor, SA, Batnagar, G, STREAMLINE COLON Investigators, STREAMLINE LUNG Investigators, METRIC Investigators, Di Ruffano, LF, Seedat, F, Clarke, A, Byron, S, Nixon, F, Albrow, R, Walker, T, Deakin, C, Zhelev, Z, Hunt, H, Yang, Y, Abel, L, Buchanan, J, Fanshawe, T, Shinkins, B, Wynants, L, Verbakel, J, Van Huffel, S, Timmerman, D, Van Calster, B, Zwinderman, A, Oke, J, O'Sullivan, J, Perera, R, Nicholson, B, Bromley, HL, Roberts, TE, Francis, A, Petrie, D, Mann, GB, Malottki, K, Smith, H, Billingham, L, Sitch, A, Gerke, O, Holm-Vilstrup, M, Segtnan, EA, Halekoh, U, Høilund-Carlsen, PF, Francq, BG, Dinnes, J, Parkes, J, Gregory, W, Hewison, J, Altman, D, Rosenberg, W, Selby, P, Asselineau, J, Perez, P, Paye, A, Bessede, E, Proust-Lima, C, Naaktgeboren, C, de Groot, J, Rutjes, A, Reitsma, J, Ogundimu, E, Cook, J, Le Manach, Y, Vergouwe, Y, Pajouheshnia, R, Groenwold, R, Peelen, L, Nieboer, D, De Cock, B, Pencina, MJ, Steyerberg, EW, Cooper, J, Parsons, N, Stinton, C, Smith, S, Dickens, A, Jordan, R, Enocson, A, Fitzmaurice, D, Adab, P, Boachie, C, Vidmar, G, Freeman, K, Connock, M, Court, R, Moons, C, Harris, J, Mumford, A, Plummer, Z, Lee, K, Reeves, B, Rogers, C, Verheyden, V, Angelini, GD, Murphy, GJ, Huddy, J, Ni, M, Good, K, Cooke, G, Hanna, G, Ma, J, Moons, KGMC, de Groot, JAH, Altman, DG, Reitsma, JB, Collins, GS, Moons, KGM, Kamarudin, AN, Kolamunnage-Dona, R, Cox, T, Borsci, S, Pérez, T, Pardo, MC, Candela-Toha, A, Muriel, A, Zamora, J, Sanghera, S, Mohiuddin, S, Martin, R, Donovan, J, Coast, J, Seo, MK, Cairns, J, Mitchell, E, Smith, A, Wright, J, Hall, P, Messenger, M, Calder, N, Wickramasekera, N, Vinall-Collier, K, Lewington, A, Damen, J, Cairns, D, Hutchinson, M, Sturgeon, C, Mitchel, L, Kift, R, Christakoudi, S, Rungall, M, Mobillo, P, Montero, R, Tsui, T-L, Kon, SP, Tucker, B, Sacks, S, Farmer, C, Strom, T, Chowdhury, P, Rebollo-Mesa, I, Hernandez-Fuentes, M, Damen, JAAG, Debray, TPA, Heus, P, Hooft, L, Scholten, RJPM, Schuit, E, Tzoulaki, I, Lassale, CM, Siontis, GCM, Chiocchia, V, Roberts, C, Schlüssel, MM, Gerry, S, Black, JA, van der Schouw, YT, Peelen, LM, Spence, G, McCartney, D, van den Bruel, A, Lasserson, D, Hayward, G, Vach, W, de Jong, A, Burggraaff, C, Hoekstra, O, Zijlstra, J, de Vet, H, Graziadio, S, Allen, J, Johnston, L, O'Leary, R, Power, M, Johnson, L, Waters, R, Simpson, J, Fanshawe, TR, Phillips, P, Plumb, A, Helbren, E, Halligan, S, Gale, A, Sekula, P, Sauerbrei, W, Forman, JR, Dutton, SJ, Takwoingi, Y, Hensor, EM, Nichols, TE, Kempf, E, Porcher, R, de Beyer, J, Hopewell, S, Dennis, J, Shields, B, Jones, A, Henley, W, Pearson, E, Hattersley, A, MASTERMIND consortium, Scheibler, F, Rummer, A, Sturtz, S, Großelfinger, R, Banister, K, Ramsay, C, Azuara-Blanco, A, Burr, J, Kumarasamy, M, Bourne, R, Uchegbu, I, Murphy, J, Carter, A, Marti, J, Eatock, J, Robotham, J, Dudareva, M, Gilchrist, M, Holmes, A, Monaghan, P, Lord, S, StJohn, A, Sandberg, S, Cobbaert, C, Lennartz, L, Verhagen-Kamerbeek, W, Ebert, C, Horvath, A, Test Evaluation Working Group of the European Federation of Clinical Chemistry and Laboratory Medicine, Jenniskens, K, Peters, J, Grigore, B, Ukoumunne, O, Levis, B, Benedetti, A, Levis, AW, Ioannidis, JPA, Shrier, I, Cuijpers, P, Gilbody, S, Kloda, LA, McMillan, D, Patten, SB, Steele, RJ, Ziegelstein, RC, Bombardier, CH, Osório, FDL, Fann, JR, Gjerdingen, D, Lamers, F, Lotrakul, M, Loureiro, SR, Löwe, B, Shaaban, J, Stafford, L, van Weert, HCPM, Whooley, MA, Williams, LS, Wittkampf, KA, Yeung, AS, Thombs, BD, Cooper, C, Nieto, T, Smith, C, Tucker, O, Dretzke, J, Beggs, A, Rai, N, Bayliss, S, Stevens, S, Mallet, S, Sundar, S, Hall, E, Porta, N, Estelles, DL, de Bono, J, CTC-STOP protocol development group, Gopalakrishna, G, Langendam, M, Scholten, R, Bossuyt, P, Leeflang, M, Noel-Storr, A, Thomas, J, Marshall, I, Wallace, B, Whiting, P, Davenport, C, GopalaKrishna, G, de Salis, I, Mallett, S, Wolff, R, Riley, R, Westwood, M, Kleinen, J, Collins, G, Reitsma, H, Moons, K, Zapf, A, Hoyer, A, Kramer, K, Kuss, O, Ensor, J, Deeks, JJ, Martin, EC, Riley, RD, Rücker, G, Steinhauser, S, Schumacher, M, Snell, K, Willis, B, Debray, T, Deeks, J, di Ruffano, LF, Taylor-Phillips, S, Hyde, C, Taylor, SA, Batnagar, G, STREAMLINE COLON Investigators, STREAMLINE LUNG Investigators, METRIC Investigators, Di Ruffano, LF, Seedat, F, Clarke, A, Byron, S, Nixon, F, Albrow, R, Walker, T, Deakin, C, Zhelev, Z, Hunt, H, Yang, Y, Abel, L, Buchanan, J, Fanshawe, T, Shinkins, B, Wynants, L, Verbakel, J, Van Huffel, S, Timmerman, D, Van Calster, B, Zwinderman, A, Oke, J, O'Sullivan, J, Perera, R, Nicholson, B, Bromley, HL, Roberts, TE, Francis, A, Petrie, D, Mann, GB, Malottki, K, Smith, H, Billingham, L, Sitch, A, Gerke, O, Holm-Vilstrup, M, Segtnan, EA, Halekoh, U, Høilund-Carlsen, PF, Francq, BG, Dinnes, J, Parkes, J, Gregory, W, Hewison, J, Altman, D, Rosenberg, W, Selby, P, Asselineau, J, Perez, P, Paye, A, Bessede, E, Proust-Lima, C, Naaktgeboren, C, de Groot, J, Rutjes, A, Reitsma, J, Ogundimu, E, Cook, J, Le Manach, Y, Vergouwe, Y, Pajouheshnia, R, Groenwold, R, Peelen, L, Nieboer, D, De Cock, B, Pencina, MJ, Steyerberg, EW, Cooper, J, Parsons, N, Stinton, C, Smith, S, Dickens, A, Jordan, R, Enocson, A, Fitzmaurice, D, Adab, P, Boachie, C, Vidmar, G, Freeman, K, Connock, M, Court, R, Moons, C, Harris, J, Mumford, A, Plummer, Z, Lee, K, Reeves, B, Rogers, C, Verheyden, V, Angelini, GD, Murphy, GJ, Huddy, J, Ni, M, Good, K, Cooke, G, Hanna, G, Ma, J, Moons, KGMC, de Groot, JAH, Altman, DG, Reitsma, JB, Collins, GS, Moons, KGM, Kamarudin, AN, Kolamunnage-Dona, R, Cox, T, Borsci, S, Pérez, T, Pardo, MC, Candela-Toha, A, Muriel, A, Zamora, J, Sanghera, S, Mohiuddin, S, Martin, R, Donovan, J, Coast, J, Seo, MK, Cairns, J, Mitchell, E, Smith, A, Wright, J, Hall, P, Messenger, M, Calder, N, Wickramasekera, N, Vinall-Collier, K, Lewington, A, Damen, J, Cairns, D, Hutchinson, M, Sturgeon, C, Mitchel, L, Kift, R, Christakoudi, S, Rungall, M, Mobillo, P, Montero, R, Tsui, T-L, Kon, SP, Tucker, B, Sacks, S, Farmer, C, Strom, T, Chowdhury, P, Rebollo-Mesa, I, Hernandez-Fuentes, M, Damen, JAAG, Debray, TPA, Heus, P, Hooft, L, Scholten, RJPM, Schuit, E, Tzoulaki, I, Lassale, CM, Siontis, GCM, Chiocchia, V, Roberts, C, Schlüssel, MM, Gerry, S, Black, JA, van der Schouw, YT, Peelen, LM, Spence, G, McCartney, D, van den Bruel, A, Lasserson, D, Hayward, G, Vach, W, de Jong, A, Burggraaff, C, Hoekstra, O, Zijlstra, J, de Vet, H, Graziadio, S, Allen, J, Johnston, L, O'Leary, R, Power, M, Johnson, L, Waters, R, Simpson, J, Fanshawe, TR, Phillips, P, Plumb, A, Helbren, E, Halligan, S, Gale, A, Sekula, P, Sauerbrei, W, Forman, JR, Dutton, SJ, Takwoingi, Y, Hensor, EM, Nichols, TE, Kempf, E, Porcher, R, de Beyer, J, Hopewell, S, Dennis, J, Shields, B, Jones, A, Henley, W, Pearson, E, Hattersley, A, MASTERMIND consortium, Scheibler, F, Rummer, A, Sturtz, S, Großelfinger, R, Banister, K, Ramsay, C, Azuara-Blanco, A, Burr, J, Kumarasamy, M, Bourne, R, Uchegbu, I, Murphy, J, Carter, A, Marti, J, Eatock, J, Robotham, J, Dudareva, M, Gilchrist, M, Holmes, A, Monaghan, P, Lord, S, StJohn, A, Sandberg, S, Cobbaert, C, Lennartz, L, Verhagen-Kamerbeek, W, Ebert, C, Horvath, A, Test Evaluation Working Group of the European Federation of Clinical Chemistry and Laboratory Medicine, Jenniskens, K, Peters, J, Grigore, B, Ukoumunne, O, Levis, B, Benedetti, A, Levis, AW, Ioannidis, JPA, Shrier, I, Cuijpers, P, Gilbody, S, Kloda, LA, McMillan, D, Patten, SB, Steele, RJ, Ziegelstein, RC, Bombardier, CH, Osório, FDL, Fann, JR, Gjerdingen, D, Lamers, F, Lotrakul, M, Loureiro, SR, Löwe, B, Shaaban, J, Stafford, L, van Weert, HCPM, Whooley, MA, Williams, LS, Wittkampf, KA, Yeung, AS, Thombs, BD, Cooper, C, Nieto, T, Smith, C, Tucker, O, Dretzke, J, Beggs, A, Rai, N, Bayliss, S, Stevens, S, Mallet, S, Sundar, S, Hall, E, Porta, N, Estelles, DL, de Bono, J, and CTC-STOP protocol development group

Abstract

[This corrects the article DOI: 10.1186/s41512-016-0001-y.].

Published
2017

47. Early enteral tube feeding in optimizing treatment for hyperemesis gravidarum (MOTHER): A multicenter open-label randomised controlled trial

Author

JC onderzoeksprogramma Methodologie, Epi Methoden Team 1, Grooten, I, Koot, M., van der Post, J., Ris-Stalpers, C., Naaktgeboren, C., Mol, B. W., Roseboom, T., Painter, R., JC onderzoeksprogramma Methodologie, Epi Methoden Team 1, Grooten, I, Koot, M., van der Post, J., Ris-Stalpers, C., Naaktgeboren, C., Mol, B. W., Roseboom, T., and Painter, R.

Published
2017

48. Low dose aspirin in the prevention of recurrent spontaneous preterm labour the APRIL study: a multicenter randomized placebo controlled trial

Author

Visser, L, de Boer, MA, de Groot, CJM, Nijman, TAJ, Hemels, MAC, Bloemenkamp, KWM, Bosmans, JE, Kok, M, van Laar, JO, Sueters, M, Scheepers, H, van Drongelen, J, Franssen, MTM, Sikkema, JM, Duvekot, J.J., Bekker, MN, van der Post, JAM, Naaktgeboren, C, Mol, BWJ (Ben), Oudijk, MA, Visser, L, de Boer, MA, de Groot, CJM, Nijman, TAJ, Hemels, MAC, Bloemenkamp, KWM, Bosmans, JE, Kok, M, van Laar, JO, Sueters, M, Scheepers, H, van Drongelen, J, Franssen, MTM, Sikkema, JM, Duvekot, J.J., Bekker, MN, van der Post, JAM, Naaktgeboren, C, Mol, BWJ (Ben), and Oudijk, MA

Published
2017

49. MisoREST: surgical versus expectant management in women with an incomplete evacuation of the uterus after misoprostol treatment for miscarriage: a randomized controlled trial

Author

Lemmers, M., Verschoor, M.A., Oude Rengerink, K., Naaktgeboren, C., Opmeer, B.C., Bossuyt, P.M., Huirne, J.A., Janssen, C.A.H., Radder, C., Klinkert, E.R., Langenveld, J., Catshoek, R., Voet, L. Van der, Siemens, F., Geomini, P., Hooff, M.H. van, Ploeg, J.M. van der, Coppus, S.F.P.J., Ankum, W.M., Mol, B.W., Lemmers, M., Verschoor, M.A., Oude Rengerink, K., Naaktgeboren, C., Opmeer, B.C., Bossuyt, P.M., Huirne, J.A., Janssen, C.A.H., Radder, C., Klinkert, E.R., Langenveld, J., Catshoek, R., Voet, L. Van der, Siemens, F., Geomini, P., Hooff, M.H. van, Ploeg, J.M. van der, Coppus, S.F.P.J., Ankum, W.M., and Mol, B.W.

Abstract

Item does not contain fulltext, STUDY QUESTION: Is curettage more effective than expectant management in case of an incomplete evacuation after misoprostol treatment for first trimester miscarriage? SUMMARY ANSWER: Curettage leads to a higher chance of complete evacuation but expectant management is successful in at least 76% of women with an incomplete evacuation of the uterus after misoprostol treatment for first trimester miscarriage. WHAT IS KNOWN ALREADY: In 5-50% of the women treated with misoprostol, there is a suspicion of incomplete evacuation of the uterus on sonography. Although these women generally have minor symptoms, such a finding often leads to additional curettage. STUDY DESIGN, SIZE, DURATION: From June 2012 until July 2014, we conducted a nationwide multicenter randomized controlled trial (RCT). Women who had had primary misoprostol treatment for miscarriage with sonographic evidence of incomplete evacuation of the uterus were randomly allocated to either curettage or expectant management (1:1), using a web-based application. PARTICIPANTS/MATERIALS, SETTING, METHODS: We included 59 women in 27 hospitals; 30 were allocated to curettage and 29 were allocated to expectant management. A successful outcome was defined as sonographic finding of an empty uterus 6 weeks after randomization. MAIN RESULTS AND THE ROLE OF CHANCE: Baseline characteristics of both groups were comparable. Empty uterus on sonography or uneventful clinical follow-up was seen in 29/30 women (97%) allocated to curettage compared with 22/29 women (76%) allocated to expectant management (RR 1.3, 95% CI 1.03-1.6) with complication rates of 10% versus 10%, respectively (RR 0.97, 95% CI 0.21-4.4). In the group allocated to curettage, no woman required re-curettage, while two women (6.7%) underwent hysteroscopy (for other or unknown reasons). In the women allocated to expectant management, curettage was performed in four women (13.8%) and three women (10.3%) underwent hysteroscopy. LIMITATIONS, REASONS FOR CAUTION: Du

Published
2016

50. MisoREST: surgical versus expectant management in women with an incomplete evacuation of the uterus after misoprostol treatment for miscarriage: a randomized controlled trial

Author

Epi Methoden Team 1, JC onderzoeksprogramma Methodologie, Lemmers, M, Verschoor, M A C, Oude Rengerink, K, Naaktgeboren, C, Opmeer, B C, Bossuyt, P M, Huirne, J A F, Janssen, C A H, Radder, C, Klinkert, E R, Langenveld, J, Catshoek, R, Van der Voet, L, Siemens, F, Geomini, P, Van Hooff, M H, Van der Ploeg, J M, Coppus, S F P J, Ankum, W M, Mol, B W J, MisoREST study group, Epi Methoden Team 1, JC onderzoeksprogramma Methodologie, Lemmers, M, Verschoor, M A C, Oude Rengerink, K, Naaktgeboren, C, Opmeer, B C, Bossuyt, P M, Huirne, J A F, Janssen, C A H, Radder, C, Klinkert, E R, Langenveld, J, Catshoek, R, Van der Voet, L, Siemens, F, Geomini, P, Van Hooff, M H, Van der Ploeg, J M, Coppus, S F P J, Ankum, W M, Mol, B W J, and MisoREST study group

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results